Ventyx Biosciences (VTYX)
(Delayed Data from NSDQ)
$2.14 USD
+0.09 (4.39%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $2.15 +0.01 (0.47%) 7:58 PM ET
1-Strong Buy of 5 1
D Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.14 USD
+0.09 (4.39%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $2.15 +0.01 (0.47%) 7:58 PM ET
1-Strong Buy of 5 1
D Value F Growth C Momentum F VGM
Zacks News
VTYX Stock Rises on Strategic Equity Investment Deal With SNY
by Zacks Equity Research
Ventyx stock climbs 7% on signing a $27 million strategic investment agreement with Sanofi in exchange for granting exclusive rights to VTX3232.
What Makes Ventyx Biosciences (VTYX) a New Buy Stock
by Zacks Equity Research
Ventyx Biosciences (VTYX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Down -86.57% in 4 Weeks, Here's Why Ventyx Biosciences, Inc. (VTYX) Looks Ripe for a Turnaround
by Zacks Equity Research
Ventyx Biosciences, Inc. (VTYX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Ventyx (VTYX) Down Despite Positive Ulcerative Colitis Study Data
by Zacks Equity Research
Ventyx Biosciences (VTYX) announces positive top-line data from a phase II study evaluating its pipeline candidate, VTX002, for treating moderate-to-severely active ulcerative colitis. Stock down.
Take the Zacks Approach to Beat the Market: Uber, Baidu, AssetMark in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Recent Price Trend in Ventyx Biosciences, Inc. (VTYX) is Your Friend, Here's Why
by Zacks Equity Research
Ventyx Biosciences, Inc. (VTYX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Wall Street Analysts See a 26.67% Upside in Ventyx Biosciences, Inc. (VTYX): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 26.7% in Ventyx Biosciences, Inc. (VTYX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Ventyx Biosciences, Inc. (VTYX) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
Ventyx Biosciences, Inc. (VTYX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Are You Looking for a Top Momentum Pick? Why Ventyx Biosciences, Inc. (VTYX) is a Great Choice
by Zacks Equity Research
Does Ventyx Biosciences, Inc. (VTYX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Think Ventyx Biosciences, Inc. (VTYX) Could Surge 38.99%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 39% upside potential for Ventyx Biosciences, Inc. (VTYX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Here's Why Momentum in Ventyx Biosciences, Inc. (VTYX) Should Keep going
by Zacks Equity Research
Ventyx Biosciences, Inc. (VTYX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Wall Street Analysts Predict a 71% Upside in Ventyx Biosciences, Inc. (VTYX): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for Ventyx Biosciences, Inc. (VTYX) points to a 70.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Ventyx Biosciences, Inc. (VTYX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Ventyx Biosciences, Inc. (VTYX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.